Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for ...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
腾讯网5 天
晚期非小细胞肺癌治疗年度进展：各种靶向药、免疫治疗药物、ADC ...
摘要本文针对2024年国内外晚期非小细胞肺癌（NSCLC）取得的临床进展进行回顾。在靶向治疗领域，特别是针对罕见突变的研究，继EGFR、ALK、ROS1等突变后的新靶点，KRAS ...
Nature1 年
Optimal first-line therapy for NSCLC with EGFR mutations
The optimal selection of patients with non-small-cell lung cancer (NSCLC) for treatment with oral small-molecule tyrosine kinase inhibitors (TKIs) has been an area of great debate. Inhibiting EGFR ...
复旦大学附属肿瘤医院发表在Oncotarget的论文被质疑图像重复使用
2014年12月， 复旦大学附属肿瘤医院 在Oncotarget期刊上发表了一篇论文。在 发表4年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor ...
Cure Today2 天
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
ophthalmologytimes14 天
Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer ...
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...
Ocean Biomedical advances in cancer immunotherapy
PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...
Healio10 天
Osimertinib linked to more therapy-related cardiac events than other TKIs for NSCLC
Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...
thecardiologyadvisor.com14 天
Risk of Cardiac Events Higher With Osimertinib Than With Other TKIs
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
Pharmabiz6 天
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...